Pluri (PLUR) Stock Price, News & Analysis

Company Overview

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies. Its PLX cell therapies have been evaluated in clinical studies targeting critical limb ischemia, hematopoietic support following radiation exposure and tissue repair in musculoskeletal injuries. The company has also received grant funding for programs addressing acute radiation syndrome and continues to explore additional indications in immune and inflammatory diseases.

Headquartered in Haifa, Israel, Pluri operates a GMP-certified manufacturing facility capable of supporting commercial-scale production. The company’s global footprint extends to clinical trial sites and partnership agreements in the United States, Europe and the Asia-Pacific region. Pluri’s leadership team brings extensive expertise in regenerative medicine, cellular manufacturing and regulatory affairs as it works toward potential market authorization and broad clinical adoption of its cell therapy products.

Key Stats

• Today's Range: $4.75 to $4.96
• 50-Day Range: $4.51 to $5.68
• 52-Week Range: $3.33 to $7.13
• Volume: 4,342 shs
• Average Volume: 19,778 shs
• Market Capitalization: $37.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Pluri Stock Analysis - MarketRank™

Pluri scored higher than 54% of companies evaluated by MarketBeat, and ranked 545th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pluri has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Pluri has a consensus price target of $12.00, representing about 152.4% upside from its current price of $4.76.

Amount of Analyst Coverage

Pluri has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pluri is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pluri is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pluri has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.61% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently decreased by 17.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pluri does not currently pay a dividend.

Dividend Growth

Pluri does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.61% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently decreased by 17.18%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.58

News Sentiment

Pluri has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Pluri this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for PLUR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Pluri to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pluri insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.93% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.59% of the stock of Pluri is held by institutions.

PLUR Stock Analysis - Frequently Asked Questions

How have PLUR shares performed this year?

Pluri's stock was trading at $4.28 at the beginning of 2025. Since then, PLUR stock has increased by 11.1% and is now trading at $4.7550.

How were Pluri's earnings last quarter?

Pluri Inc. (NASDAQ:PLUR) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.94) earnings per share for the quarter. The firm earned $0.43 million during the quarter. Pluri had a negative trailing twelve-month return on equity of 4,191.91% and a negative net margin of 2,563.29%.

When did Pluri's stock split?

Pluri's stock reverse split on Monday, April 1st 2024.The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Pluri?

Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pluri own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pluri investors own include Digital Turbine (APPS), Lightning eMotors (ZEV), Archer Aviation (ACHR), ChargePoint (CHPT) and Canoo (GOEV).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 9/17/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PLUR
• CIK: 1158780
• Web: pluri-biotech.com
• Phone: 972747108600
• Fax: 972-74-710-8787
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pluri: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +152.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.89 million
• Net Margins: -2,563.29%
• Pretax Margin: -1,789.02%
• Return on Equity: -4,191.91%
• Return on Assets: -85.40%

Debt

• Debt-to-Equity Ratio: 51.65
• Current Ratio: 4.81
• Quick Ratio: 4.81

Sales & Book Value

• Annual Sales: $330 thousand
• Price / Sales: 113.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 4.76

Miscellaneous

• Outstanding Shares: 7,870,000
• Free Float: 5,830,000
• Market Cap: $37.42 million
• Optionable: Optionable
• Beta: 0.69